Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 10/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20869211 | 0.78 | PDE4B (0.48) | PDE4BTGFBR1LMNAKDM4ECXCR4 | |
| SCHEMBL5699906 | 0.76 | MEN1 (0.41) | TGFBR1KDM4ENPC1RAB9A | |
| SCHEMBL30971512 | 0.74 | TRPV1 (0.40) | PDE4BLMNAKDM4ECXCR4GAA | |
| SCHEMBL3772488 | 0.74 | TRPV1 (0.40) | PDE4BLMNAKDM4ECXCR4GAA | |
| Formamide SCHEMBL22289820 | 0.71 | NOS3 (0.41) | LMNAKDM4ECXCR4GAANPC1 | |
| SCHEMBL25211504 | 0.70 | TGFBR1 (0.38) | PDE4BTGFBR1LMNAKDM4ECXCR4 | |
| SCHEMBL30469190 | 0.70 | TGFBR1 (0.38) | PDE4BTGFBR1LMNAKDM4ECXCR4 | |
| SCHEMBL20869165 | 0.69 | PDE4B (0.53) | PDE4BLMNAPDE4APDE4CPDE4D | |
| SCHEMBL5335078 | 0.69 | GAA (0.38) | LMNAKDM4ECXCR4GAANPC1 | |
| SCHEMBL12958179 | 0.69 | MCHR1 (0.40) | PDE4BTGFBR1LMNAKDM4ECXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | PDE4B 1486/4885TGFBR1 4690/4885LMNA 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.